- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- EACR 21
- MBCC 12
- EHA 2010
- ASCO 2010
- ELCC 2010
- AACR 2010
- EMCCC 2010
- EBCC 7
- DKK 2010
- ASH 2009
- SABCS 2009
- AORTIC
- NCRI
- ECCO 15 - ESMO 34
- 11th Milan Breast Cancer Conference 2009
- IMPAKT
- ASCO 2009
- AACR 2009
- SABCS 2008
- ASH 50th annual meeting 2008
- ESMO 33
- 10th Milan Breast Cancer Conference 2008
- EBCC 6 2008
- ECCO 14 2007
- By continent
- Latest technologies
- Education
- Most viewed
- View all
Latest
Professor Chris Twelves - St James's Hospital, Leeds, UK
New agent eribulin prolongs survival in metastatic breast cancer
A new study presented at ASCO has found that eribulin can extend the survival rates of women with locally recurrent or metastatic breast cancer in women who have already received extensive standard therapy. Prof Twelves who helped designed the trial talks to Prof McVie about the findings.
Supported by an educational grant from Eisai Pharma Europe Ltd.
Click here to watch Prof Christopher Twelves' press briefing from ASCO 2010
Congress » ASCO 2010
Other Congress
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment